Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871382 | 0.94 | PDK2 (0.36) | PDK2ACLYORAI1DHODHCA1 | |
| SCHEMBL21863425 | 0.94 | PDK2 (0.36) | PDK2ACLYORAI1DHODHCA1 | |
| SCHEMBL869871 | 0.90 | PDK2 (0.40) | PDK2CA1CA2EPAS1 | |
| SCHEMBL13458407 | 0.89 | PDK2 (0.33) | PDK2ORAI1DHODH | |
| SCHEMBL30313890 | 0.89 | ACLY (0.38) | PDK2ACLYORAI1DHODH | |
| SCHEMBL2780339 | 0.89 | ACLY (0.38) | PDK2ACLYORAI1DHODH | |
| SCHEMBL870558 | 0.88 | LTB4R (0.32) | PDK2CA1CA2 | |
| SCHEMBL10072339 | 0.88 | HPGD (0.35) | PDK2ORAI1CA1CA2 | |
| SCHEMBL871282 | 0.88 | PDK2 (0.37) | PDK2ORAI1CA1CA2 | |
| SCHEMBL1936965 | 0.88 | FABP4 (0.34) | PDK2ACLYORAI1DHODHCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2619189-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | Zoetis LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012038851-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012038851-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | PDK2 618/4885ACLY 1356/4885ORAI1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.